vs
Side-by-side financial comparison of Mirum Pharmaceuticals, Inc. (MIRM) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $148.9M, roughly 1.7× Mirum Pharmaceuticals, Inc.). WESBANCO INC runs the higher net margin — 34.5% vs -3.8%, a 38.3% gap on every dollar of revenue. Over the past eight quarters, Mirum Pharmaceuticals, Inc.'s revenue compounded faster (46.7% CAGR vs 31.9%).
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
MIRM vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $148.9M | $257.2M |
| Net Profit | $-5.7M | $88.6M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | — |
| Net Margin | -3.8% | 34.5% |
| Revenue YoY | 49.8% | — |
| Net Profit YoY | 75.9% | 54.4% |
| EPS (diluted) | $-0.10 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $148.9M | $265.6M | ||
| Q3 25 | $133.0M | $261.6M | ||
| Q2 25 | $127.8M | $260.7M | ||
| Q1 25 | $111.6M | $193.2M | ||
| Q4 24 | $99.4M | $162.9M | ||
| Q3 24 | $90.4M | $150.8M | ||
| Q2 24 | $77.9M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-5.7M | $91.1M | ||
| Q3 25 | $2.9M | $83.6M | ||
| Q2 25 | $-5.9M | $57.4M | ||
| Q1 25 | $-14.7M | $-9.0M | ||
| Q4 24 | $-23.8M | $49.6M | ||
| Q3 24 | $-14.2M | $37.3M | ||
| Q2 24 | $-24.6M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | -3.1% | 43.2% | ||
| Q3 25 | 2.0% | 39.5% | ||
| Q2 25 | -3.9% | 27.2% | ||
| Q1 25 | -13.6% | -5.0% | ||
| Q4 24 | -24.4% | 38.0% | ||
| Q3 24 | -14.0% | 29.7% | ||
| Q2 24 | -31.1% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -3.8% | 34.3% | ||
| Q3 25 | 2.2% | 31.9% | ||
| Q2 25 | -4.6% | 22.0% | ||
| Q1 25 | -13.2% | -4.7% | ||
| Q4 24 | -23.9% | 30.5% | ||
| Q3 24 | -15.8% | 24.7% | ||
| Q2 24 | -31.6% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.10 | $0.97 | ||
| Q3 25 | $0.05 | $0.84 | ||
| Q2 25 | $-0.12 | $0.57 | ||
| Q1 25 | $-0.30 | $-0.15 | ||
| Q4 24 | $-0.49 | $0.72 | ||
| Q3 24 | $-0.30 | $0.54 | ||
| Q2 24 | $-0.52 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $383.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $314.7M | $4.1B |
| Total Assets | $842.8M | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $383.3M | $956.1M | ||
| Q3 25 | $375.5M | $1.0B | ||
| Q2 25 | $304.6M | $1.2B | ||
| Q1 25 | $277.7M | $1.1B | ||
| Q4 24 | $280.3M | $568.1M | ||
| Q3 24 | $284.4M | $620.9M | ||
| Q2 24 | $278.4M | $486.8M |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $314.7M | $4.0B | ||
| Q3 25 | $292.0M | $4.1B | ||
| Q2 25 | $255.2M | $3.8B | ||
| Q1 25 | $233.3M | $3.8B | ||
| Q4 24 | $225.6M | $2.8B | ||
| Q3 24 | $232.0M | $2.8B | ||
| Q2 24 | $229.0M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $842.8M | $27.7B | ||
| Q3 25 | $785.1M | $27.5B | ||
| Q2 25 | $725.8M | $27.6B | ||
| Q1 25 | $690.2M | $27.4B | ||
| Q4 24 | $670.8M | $18.7B | ||
| Q3 24 | $667.9M | $18.5B | ||
| Q2 24 | $660.8M | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $6.1M | — |
| Free Cash FlowOCF − Capex | $5.5M | — |
| FCF MarginFCF / Revenue | 3.7% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $54.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $6.1M | $290.4M | ||
| Q3 25 | $39.7M | $116.9M | ||
| Q2 25 | $12.0M | $105.0M | ||
| Q1 25 | $-2.0M | $-26.4M | ||
| Q4 24 | $-5.1M | $211.0M | ||
| Q3 24 | $4.0M | $60.7M | ||
| Q2 24 | $-3.8M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $5.5M | $280.0M | ||
| Q3 25 | $39.5M | $114.9M | ||
| Q2 25 | $11.9M | $98.3M | ||
| Q1 25 | $-2.0M | $-30.7M | ||
| Q4 24 | $-5.1M | $200.7M | ||
| Q3 24 | $3.8M | $56.9M | ||
| Q2 24 | $-4.6M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 105.4% | ||
| Q3 25 | 29.7% | 43.9% | ||
| Q2 25 | 9.3% | 37.7% | ||
| Q1 25 | -1.8% | -15.9% | ||
| Q4 24 | -5.1% | 123.2% | ||
| Q3 24 | 4.2% | 37.7% | ||
| Q2 24 | -5.9% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 3.9% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.0% | 2.2% | ||
| Q4 24 | 0.0% | 6.3% | ||
| Q3 24 | 0.2% | 2.5% | ||
| Q2 24 | 1.0% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | 13.66× | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MIRM
| Livmarli | $106.4M | 71% |
| Bile Acid Medicines | $42.5M | 29% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
